Phase 1/2 Study: Safety and Efficacy of Belantamab Mafodotin +Rd Presented at EHA 2022

Prof. Evangelos Terpos Discusses Safety and Efficacy of Belantab Mafodotin + Rd in Newly Diagnosed Transplant-Ineligible Myeloma Patients

Abstract Title:

A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma transplant ineligible.

In this video:

Prof. Evangelos Terpos (Department of Clinical Therapeutics, University of Athens, School of Medicine—Athens, Greece) discusses safety and efficacy of belantab mafodotin (Blenrep, belamaf) plus lenalidomide and dexamethasone (Rd) in newly diagnosed transplant-ineligible multiple myeloma (ND TI MM) patients 

What is the purpose of this trial? 

To evaluate the safety and efficacy of belantamab mafodotin (Blenrep, belamaf) plus lenalidomide and dexamethasone (Rd) in newly diagnosed transplant-ineligible multiple myeloma (ND TI MM) patients.

This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with lenalidomide and dexamethasone. 

The study is comprised of two distinct parts: Part 1 evaluates different doses of belantamab mafodotin in combination with lenalidomide and dexamethasone (Rd) in up to 3 cohorts and will determine the recommended Phase 2 dose (RP2D) to be further evaluated for safety and clinical activity in the dose expansion cohort (Part 2). The RP2D dose will be used for future studies in the transplant-ineligible newly diagnosed multiple myeloma setting. Part 2 of the study will also evaluate an alternative dose modification guideline for corneal adverse events. 

Conclusion:

In ND TI MM patients, belamaf every 2 months plus Rd showed an improved safety profile, especially at lower doses. Rapid and deep hematological responses were recorded.

Clinical trial information: NCT04808037

Doctor Bio:

Evangelos Terpos, MD, PhD is a Professor of Haematology in the Department of Clinical Therapeutics in the University of Athens, School of Medicine in Athens, Greece. Dr Terpos has given lectures at EHA & ASH meetings, International Myeloma Workshops, International Meetings on Cancer-Induced Bone Disease and in several national meetings. He is reviewer of scientific papers in more than 50 medical journals and has reviewed abstracts for EHA and ASH meetings. He is associate editor for Myeloma in Hemasphere (official journal of EHA) since 2017.